The central drugs laboratories found 42 drug samples manufactured by various firms to be "not of standard quality (NSQ)" in its monthly drug alert for April, Union health ministry officials said on Thursday. Further, the state drug testing laboratories have identified 127 drug samples as NSQ, they said.
The Central Drugs Laboratories identified 60 drug samples as 'not of standard quality' in February, while state labs found 134 substandard samples. Investigations are underway for spurious drugs manufactured by unauthorised companies.
Among the commonly used analgesic formulations (painkillers) found NSQ are combinations of paracetamol with ibuprofen, diclofenac and mefenamic acid. Medications using these combinations are commonly used to treat fever, mild migraine, period and muscle pain.
'Anti-cancer, anti-diabetic, and other drugs suspected to be spurious were seized from the raid carried out at the firm.'
Rise in raids on illicit drug manufacturing units, alongside arrests for the production, sale, or distribution of spurious or adulterated drugs.
Indian pharmaceutical companies are stepping up their efforts to combat the problem of counterfeit drugs, employing a variety of strategies, from packaging innovations to engaging private investigation agencies. The stakes are high, as counterfeit medicines not only harm consumers but also tarnish the reputation of leading brands.
The percentage of non-standard quality drugs in the state has been in the range of 2-2.5% as compared to an all-India average of 5-6%
